Permeon Biologics develops intracellular biologics via its proprietary Intraphilin Technology Platform, which enables delivery of supercharged proteins directly or via covalent conjugation or complexing with active proteins and nucleic acids. The platform is intended to create potent intracellular therapeutic agents without cytotoxicity. The company says its approach can enable a new generation of therapeutic drugs to enhance human health. Permeon is headquartered in Cambridge, MA. The filing notes a recent financing event, indicating the company is raising outside capital and debt to support its programs. No operating metrics or prior financing details are provided in the article.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2012